Clinical Trial Update: Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma [Phase 1]

View source ↗

Summary

This update reports completion of a Phase 1 trial evaluating a triple combination of MEK, STAT3, and PD-1 pathway inhibition in metastatic pancreatic ductal ade…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Snippet

Sponsor: Peter Hosein, MD | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: COMPLETED